|
|
 Previous Article | Table of Contents | Next Article 
Antiproliferative effects of interleukin-4 on freshly isolated non- Hodgkin
malignant B-lymphoma cells
T Defrance, AC Fluckiger, JF Rossi, JP Magaud, JJ Sotto and J Banchereau
Schering-Plough, Laboratory for Immunological Research, Dardilly, France.
The pattern of in vitro growth response of freshly isolated non-Hodgkin
malignant lymphoma B cells (NHML) to cytokines was investigated. Ten tumor
specimens of low- or intermediate-grade malignancy were selected for study.
To assess their proliferative capacity in vitro, B-lymphoma cells were
activated through ligation of their surface Ig receptor with insolubilized
anti-IgM antibodies or Staphylococcus aureus strain Cowan I (SAC). In the
great majority of cases, interleukin-2 (IL-2) was the sole factor that
significantly and reproducibly stimulated DNA synthesis in NHML activated
through their surface Igs. Other B-cell tropic factors, including IL-4,
IL-5, IL-6, and tumor necrosis factor- alpha (TNF-alpha), failed to elicit
a growth response in most of the IL- 2-responsive neoplastic samples.
However, one specimen among 10 exhibited the opposite pattern of response
and proliferated following culture with IL-4 and anti-Ig reagents, but not
after IL-2 stimulation. Three specimens could also be induced for DNA
synthesis on cross- linking of their surface Igs in the absence of
exogenous growth factors. Although IL-4 could not support the in vitro
growth of the majority of NHML cases, it strongly suppressed the
proliferative signals delivered to these cells by anti-Ig reagents used
alone or in combination with IL-2. Our data suggest that, in most cases,
IL-4 essentially provides growth-inhibitory signals to NHML when they are
activated through their surface Ig receptors and as such may be considered
to be a valid candidate for future therapy of this type of mature B-cell
malignancy.
Volume 79,
Issue 4,
pp. 990-996,
02/15/1992
Copyright © 1992 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. R. Calvo, B. Dabir, A. Kovach, C. Devor, R. Bandle, A. Bond, J. H. Shih, and E. S. Jaffe
IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma
Blood,
November 1, 2008;
112(9):
3818 - 3826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Schenten, A. Egert, M. Pasparakis, and K. Rajewsky
M17, a gene specific for germinal center (GC) B cells and a prognostic marker for GC B-cell lymphomas, is dispensable for the GC reaction in mice
Blood,
June 15, 2006;
107(12):
4849 - 4856.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Lu, H. Nechushtan, F. Ding, M. F. Rosado, R. Singal, A. A. Alizadeh, and I. S. Lossos
Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas
Blood,
April 1, 2005;
105(7):
2924 - 2932.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Lossos, A. A. Alizadeh, R. Rajapaksa, R. Tibshirani, and R. Levy
HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma
Blood,
January 15, 2003;
101(2):
433 - 440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
